The Australian Register of Therapeutic Goods communicated its decision to approve the registration submitted by licensee Solvay Biosciences of Zan-Extra in its two dosage forms containing lercanidipine 10mg/enalapril 10mg and lercanidipine 10mg/enalapril 20mg. The launch in Australia of this new product originated by Recordati is planned to take place in April.
Giovanni Recordati, chairman and CEO of Recordati, said: “We are expecting the outcome of the mutual recognition procedure in Europe shortly and this will allow us to launch the product throughout the EU.”